Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Clinical trial NCT03322267 · COMPLETED
Trial details
- NCT number
- NCT03322267
- Sponsor
- National Taiwan University Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-27
- Primary completion
- 2024-01-31
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.